Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.64 |
| ▸ | STK39 | Q9UEW8 | 10/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | PARG | Q86W56 | 2/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.54 |
| ▸ | PNLIP | P16233 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658654 | 0.87 | PTGS1 (0.61) | PTGS1TBXAS1MAPK1PTGS2MAPK14 | |
| SCHEMBL5655299 | 0.85 | PTGS1 (0.59) | PTGS1TBXAS1MAPK1PTGS2MAPK14 | |
| SCHEMBL649911 | 0.84 | PTGS1 (0.77) | PTGS1TBXAS1MAPK1PTGS2MAPK14 | |
| SCHEMBL29375129 | 0.84 | PTGS1 (0.77) | PTGS1TBXAS1MAPK1PTGS2MAPK14 | |
| SCHEMBL9868077 | 0.83 | STK39 (0.77) | PTGS1TBXAS1MAPK1PTGS2MAPK14 | |
| Hydrochloric Acid SCHEMBL11777767 | 0.81 | STK39 (0.75) | PTGS1TBXAS1MAPK1PTGS2MAPK14 | |
| SCHEMBL19077944 | 0.81 | PTGS1 (0.60) | PTGS1TBXAS1MAPK1PTGS2MAPK14 | |
| SCHEMBL25413048 | 0.80 | PTGS1 (0.71) | PTGS1TBXAS1MAPK1PTGS2MAPK14 | |
| SCHEMBL10457403 | 0.80 | PARG (0.71) | PTGS1TBXAS1MAPK1PTGS2MAPK14 | |
| SCHEMBL11692717 | 0.80 | PTGS1 (0.71) | PTGS1TBXAS1MAPK1PTGS2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | LE ROUX DANIELLE MARIE (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20090324540-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090324540-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-7553872-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553872-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7071214-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | VIP, GIPR, SLC10A2 | PTGS1 948/4885TBXAS1 4259/4885MAPK1 2609/4885 |
| US-20090324540-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | ABCB4, ABCB7, ALPP | PTGS1 1784/4885TBXAS1 1375/4885MAPK1 4648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.